文献速递消化道肿瘤放疗放疗物理与技术

局部晚期不可切除胰腺癌CyberKnife立体定向放疗剂量递增I期研究方案

Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study.
PubMed 文献 · Radiat Oncol · 2017-01-09

本研究为单中心I期试验,旨在确定CyberKnife立体定向放疗五分割治疗局部晚期不可切除胰腺癌的最大耐受剂量,主要终点为III/IV级胃肠道毒性频率。剂量水平从7 Gy至9.5 Gy每分割共5次,每剂量组至少3例患者,剂量递增间隔4周。最大耐受剂量定义为3例中至少2例或9例中至少3例出现限制性毒性。

要点

  • 五分割SBRT剂量递增范围7 Gy至9.5 Gy每分割,共5次。
  • 主要终点为III/IV级胃肠道毒性确定最大耐受剂量。
  • 每剂量组至少3例,剂量递增间隔4周。

核心结论

  • 研究旨在确定CyberKnife五分割SBRT治疗局部晚期不可切除胰腺癌的最大耐受剂量。

研究设计与样本

  • 单中心I期研究,每剂量组至少3例患者,剂量递增间隔4周。
  • 剂量水平为7 Gy、7.5 Gy、8 Gy、8.5 Gy、9 Gy、9.5 Gy每分割共5次。

主要发现

  • 主要终点为根据CTC第4版评估的III/IV级胃肠道毒性频率。
  • 最大耐受剂量定义为3例中至少2例或9例中至少3例出现限制性毒性。

关键数值与推荐

  • 剂量递增需满足正常组织约束。
  • 不良事件按Common Toxicity Criteria第4版评估。

临床怎么用

  • 该方案为局部晚期胰腺癌SBRT剂量探索提供I期试验框架。

局限性

  • 原文未报告研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dose escalation of SBRT for locally advanced pancreatic cancer patients had been reported in several studies in one or three fractions, and phase I protocol was developed to investigate the maximum tolerated dose with CyberKnife for locally advanced unresectable pancreatic cancer patients in five fractions. METHODS: The study is designed as a mono-center phase I study. The primary endpoint is to determine the maximum tolerated dose by frequency of III/IV GI (gastrointestinal) toxicity. Adverse events (AE) according to Common Toxicity Criteria (CTC) version 4. Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5Gy x 5 respectively would be delivered while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is 4 weeks from the first patient treatment to the next patient treatment at each dose level. The maximal tolerated dose will be defined as the dose for which at least two patients in three, or at least three patients in nine, will present with a limiting toxicity. DISCUSSION: Since the dose and fractions of SBRT treatment for locally advanced pancreatic cancer patients are still unknown, we propose to conduct a Phase I study determining the maximum tolerated dose of CyberKnife SBRT for the treatment of locally advanced pancreatic tumor based on a 5 fractions treatment regimen. This trial protocol has been approved by the Ethics committee of Changhai hospital. The ethics number is 2016-030-01. TRIAL REGISTRATION: Clinical trials number: NCT02716207 . Date of registration: 20 March 2016.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Qing SW, Ju XP, Cao YS, et al. Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I study. Radiat Oncol. 2017. PMID: 28069017. doi:10.1186/s13014-016-0760-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。